• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by IO Biotech Inc.

    4/25/25 4:05:46 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IOBT alert in real time by email
    DEFA14A 1 iobt_defa14a_2025.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    IO BIOTECH, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


     

    img59693029_0.jpg

     

    LOGO IO BIOTECH, INC. OLE MAALØES VEJ 3 DK-2200 COPENHAGEN N DENMARK Your Vote Counts! IO BIOTECH, INC. 2025 Annual Meeting Vote by June 4, 2025 11:59 PM ET V74606-P25213 You invested in IO BIOTECH, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 5, 2025. Get informed before you vote View the Notice & Proxy Statement and Form-10K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 5, 2025 8:30 AM, Eastern Time Virtually at: www.virtualshareholdermeeting.com/IOBT2025 *Please check the meeting materials for any special requirements for meeting attendance.

     


     

    img59693029_1.jpg

     


    Get the next $IOBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IOBT

    DatePrice TargetRatingAnalyst
    1/26/2026$0.50Overweight → Neutral
    Piper Sandler
    1/8/2026$0.36Equal-Weight → Underweight
    Morgan Stanley
    9/30/2025$0.39Overweight → Equal-Weight
    Morgan Stanley
    9/30/2025Buy → Hold
    TD Cowen
    11/30/2021$21.00Overweight
    Morgan Stanley
    11/30/2021Outperform
    Cowen & Co.
    11/30/2021$20.00Buy
    Jefferies
    More analyst ratings

    $IOBT
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by IO Biotech Inc.

    SCHEDULE 13G - IO Biotech, Inc. (0001865494) (Subject)

    2/6/26 4:10:31 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by IO Biotech Inc.

    8-K - IO Biotech, Inc. (0001865494) (Filer)

    1/30/26 4:53:41 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by IO Biotech Inc.

    SCHEDULE 13D/A - IO Biotech, Inc. (0001865494) (Subject)

    1/23/26 7:05:19 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hunter Heidi bought $20,884 worth of shares (15,000 units at $1.39) (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/2/25 7:53:36 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Ahmad Qasim Iftikhar bought $26,553 worth of shares (31,350 units at $0.85) (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    12/26/24 8:50:34 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Zocca Mai-Britt bought $10,120 worth of shares (12,500 units at $0.81), increasing direct ownership by 33% to 49,891 units (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    12/23/24 6:56:14 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IO Biotech Provides Corporate Update

    Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company's workforce, to reduce operating expenses while the company explores strategic al

    1/30/26 8:05:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces Exploration of Strategic Alternatives

    NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, a merger, a business combination, a sale of assets or other strategic transaction or a liquidation and dissolution. The company is also evaluating a further reduction-in-force and other efforts to significantly reduce the company's operating expenses while the company explores a range of strategic alternative

    1/21/26 5:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

    Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free survival was 25.5 monthsThese results reinforce the potential of immune-modulatory vaccination NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the publication in Nature Communications of the long-term clinical and immunological outcomes from MM1636, the Phase 1/2 trial evaluating the investigational peptide vaccine IO102-IO103 targeting both

    12/15/25 4:05:00 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    IO Biotech downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded IO Biotech from Overweight to Neutral and set a new price target of $0.50

    1/26/26 10:01:23 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded IO Biotech from Equal-Weight to Underweight and set a new price target of $0.36

    1/8/26 8:40:06 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech downgraded by TD Cowen

    TD Cowen downgraded IO Biotech from Buy to Hold

    9/30/25 8:32:59 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Smith David V

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:27:46 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunter Heidi

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:27:20 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hirth Peter

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:26:55 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Leadership Updates

    Live Leadership Updates

    View All

    IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

    -- Enrollment Completed Ahead of Schedule --       -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial (IOB-032/PN-E40). The trial is studying IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), given before (neoadjuvant) and after (adjuvant) surgery with curative intent in patients with resectab

    1/9/25 8:05:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

    NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia

    4/15/24 8:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

    NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. "We are very excited to welcome

    4/5/24 8:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IO Biotech Inc.

    SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

    11/13/24 5:30:28 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by IO Biotech Inc.

    SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)

    9/17/24 9:01:25 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by IO Biotech Inc. (Amendment)

    SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

    5/14/24 9:35:27 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Financials

    Live finance-specific insights

    View All

    IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

    Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months for the cont

    8/11/25 8:00:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

    NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma. Webcast and Conference Call Information The IO Biotech management team will host a webcast/conference call

    8/10/25 8:00:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

    Enrollment in the company's Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States.The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and nec

    3/14/23 4:11:47 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care